Again, positive nodes were found to be a significant risk of earlier distant relapse (HR 1.42; 1.05–1.93; p = 0.024), whilst patients with HER2-positive tumours had longer survival (HR 0.66; 0.51–0.86; p = 0.002). This evidence concerns the gene ERBB2 and neoplasm.